X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement with Genpharm advances Albireo’s global strategy for the commercialization of Bylvay in a key region following European and U.S. regulatory approvals of the use of Bylvay in patients with PFIC based on the PEDFIC study.
Lead Product(s): Odevixibat
Therapeutic Area: Genetic Disease Product Name: Bylvay
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Albireo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 18, 2021
Details:
Under terms of the agreements, GenPharm and GEN will be responsible for all activities related to identifying patients, driving disease awareness, and ensuring market access for Libmeldy in their respective territories.
Lead Product(s): Autologous CD34+ cell enriched HSPC
Therapeutic Area: Genetic Disease Product Name: Libmeldy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Orchard Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
